Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5.  Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of

Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention

The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

The Journal of Headache and Pain 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4. M Lanteri-Minet, R Fabre, C Martin, K Pradat, A Alchaar, E Bozzolo, M L Duchene, E K Van Obberghen, A Donnet, D Fontaine Abstract Background: Randomized clinical trials have

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study

The Journal of Headache and Pain 2023 Nov 8;24(1):151. doi: 10.1186/s10194-023-01683-1. Richard B Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L Reed, Kristina M Fanning, Dawn C Buse Abstract Background: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as

Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care

Cephalalgia 2023 Jun;43(6):3331024231180611.doi: 10.1177/03331024231180611. Aubrey Manack Adams, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Zaza Katsarava, Michael L Reed, Kristina Fanning, Katherine Sommer, Richard B Lipton Abstract Background: The Chronic Migraine Epidemiology and Outcomes-International study provides insight into people with migraine in multiple countries. Methods:

Radiosurgery for classical trigeminal neuralgia: impact of the shot size on clinical outcome

The Journal of Headache and Pain 2023 May 11;24(1):51.doi: 10.1186/s10194-023-01583-4. Cécile Ortholan, Philippe Colin, Benjamin Serrano , Thibault Bouet, Nicolas Garnier, Maud le Guyader, Regis Amblard, Rémy Villeneuve, Stéphane Chanalet, Haiel Alchaar, Eric Bozzolo, Michel Lanteri-Minet, Denys Fontaine Abstract Background: This study compares the outcome of patients suffering from medically refractory classical

Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Cephalalgia 2023 May;43(5):3331024231170807.doi: 10.1177/03331024231170807. Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich Abstract Background: Migraine is a disabling neurological disease adversely affecting many aspects of life. Most patients are still required to have failed several older oral

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data

Cephalalgia 2022 Sep 8;3331024221123058. doi: 10.1177/03331024221123058. Online ahead of print. Michel Lanteri-Minet, Anne Ducros , Clement Francois, Elzbieta Olewinska, Mateusz Nikodem, Laure Dupont-Benjamin Abstract Background: This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.